ReviewAmerican journal of nuclear medicine and molecular imaging2019
Radionuclide generators: the prospect of availing PET radiotracers to meet current clinical needs and future research demands.
Review in American journal of nuclear medicine and molecular imaging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 45 citations in OpenAlex.
- A comparative evaluation of chemical processes in anion exchange-basedEJNMMI radiopharmacy and chemistry · 2026Article
- TheEJNMMI radiopharmacy and chemistry · 2026Article
- Long-term performance evaluation of a novel 3.26 GBqEJNMMI radiopharmacy and chemistry · 2026Article
- Alpha and Beta Emitters in Translational Nuclear Medicine: Clinical Advances, Challenges, and Future Direction.International journal of molecular sciences · 2026Review
- Increasing the activity output and optimization of automated radiosynthesis [EJNMMI radiopharmacy and chemistry · 2026Article
- Review
- Modernizing Neuro-Oncology: The Impact of Imaging, Liquid Biopsies, and AI on Diagnosis and Treatment.International journal of molecular sciences · 2025Review
- Platinum group metals for nuclear medicine, a luxurious dream or the future of imaging and therapy: a review.Frontiers in nuclear medicine · 2025Review
- Rapid Concentration of Ga-68 and Proof-of-Concept Microscale Labeling of [Molecules (Basel, Switzerland) · 2024Article
- SyntheticRSC medicinal chemistry · 2024Review
- Medicinal (Radio) Chemistry: Building Radiopharmaceuticals for the Future.Current medicinal chemistry · 2024Review
- Membrane-based microfluidic solvent extraction of Ga-68 from aqueous Zn solutions: towards an automated cyclotron production loop.EJNMMI radiopharmacy and chemistry · 2023Article
- Preclinical PET Imaging and Toxicity Study of aPharmaceutics · 2023Article
- Radiolabeled nanomaterial for cancer diagnostics and therapeutics: principles and concepts.Cancer nanotechnology · 2023Review
- Current State ofCurrent radiopharmaceuticals · 2023Review
- Left Ventricular Myocardial and Cavity Velocity Disturbances Are Powerful Predictors of Significant Coronary Artery Stenosis.Journal of clinical medicine · 2022Article
- Production of GMP-Compliant Clinical Amounts of Copper-61 Radiopharmaceuticals from Liquid Targets.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Prospect of positron emission tomography for abdominal aortic aneurysm risk stratification.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021Review
- Towards Facile Radiolabeling and Preparation of Gallium-68-/Bismuth-213-DOTA-[ThiPharmaceutics · 2021Article
- ImmunoPET of the differential expression of CD146 in breast cancer.American journal of cancer research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Targeted molecular imaging with positron emission tomography (PET) constitutes a successful technique for detecting and diagnosing disease conditions promptly and accurately, and for effectively prognosticating outcomes and treating patients with a tailored and more individualized intervention. In order to expand the success of PET in nuclear medicine, it is important to assure access to radiotracers of desired quantities and qualities. In this context, the benefit of accessing PET radiotracers through a radionuclide generator (RNG) cannot be overstated, as generators offer the potential of enriching the PET radiotracer arsenal at the medical centers both with and without onsite cyclotrons. While RNG technology to avail PET tracers is in its infancy, their use is expected to revitalize current PET practices and seems poised to broaden the palette of PET in nuclear medicine in the foreseeable future. In this review, we discuss the principles of RNGs, assess major parent/daughter pairs of interest for PET, RNGs currently in use in clinical PET, and identify the potentially useful RNGs which have made substantial progress or are likely to be used in daily clinical practices in the near future. Availability of the parent radionuclides required for PET RNGs is an important criterion and hence their production will also be reviewed. This overview outlines a critical assessment of RNGs to avail PET tracers, the contemporary status of RNGs, and key challenges and apertures to the near future.
Indexed as
Identifiers
30911436PMC6420712W2996387854What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.